Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 333-347 , April 2006

In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction

Received 29 September 2005 ,Revised 8 December 2005 ,Accepted 8 December 2005.

References 

  1. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095–3105
  2. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087–4091
  3. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285–4289
  4. Carter P, Rodrigues ML, Lewis GD, Figari I, Shalaby MR. Towards an immunotherapy for p185HER2 overexpressing tumors. Adv Exp Med Biol. 1994;353:83–94
  5. Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs. 2001;12(Suppl 4):S3–S10
  6. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001;28:43–47
  7. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer. 2001;37(Suppl 1):S18–S24
  8. Zalutsky MR. Growth factor receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:71–77
  9. Zalutsky MR. Radionuclide therapy. In:  Roesch F editors. Handbook of nuclear chemistry. Radiochemistry and radiopharmaceutical chemistry in life sciences. vol. 4:Dordrecht: Kluwer Academic Publishers; 2003;p. 315–348
  10. Braun S, Hepp F, Sommer HL, Pantel K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer. 1999;84:1–5
  11. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:255–263
  12. Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, et al. Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 2004;10:4489–4497
  13. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1993;24:85–95
  14. Zalutsky MR, Zhao XG, Alston KL, Bigner D. High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use. J Nucl Med. 2001;42:1508–1515
  15. Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. Cancer Res. 1989;49:5543–5549
  16. Li Y, Wood N, Yellowlees D, Donnelly PK. Cell surface expression of urokinase receptor in normal mammary epithelial cells and breast cancer cell lines. Anticancer Res. 1999;19:1223–1228
  17. Lenkei R, Gratama JW, Rothe G, Schmitz G, D'Hautcourt JL, Arekrans A, et al. Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry. 1998;33:188–196
  18. Arteaga CL. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res. 2003;5:96–100
  19. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 2003;63:1130–1137
  20. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem. 2003;278:23343–23351
  21. Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol. 2000;18:194–198
  22. Wiley HS, Cunningham DD. The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis. J Biol Chem. 1982;257:4222–4229
  23. Sato Y, Takahashi M, Shibukawa Y, Jain SK, Hamaoka R, Miyagawa J, et al. Overexpression of N-acetylglucosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up-regulation of the internalization rate of the receptors. J Biol Chem. 2001;276:11956–11962
  24. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63:5084–5090
  25. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2:1113–1120
  26. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther. 2003;2:353–360
  27. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol. 2002;13:65–72
  28. Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. J Biophys. 2003;85:2732–2745
  29. Wu JT. C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta. 2002;322:11–19
  30. Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001;7:3239–3250
  31. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, et al. Enhanced sensitization to taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 2002;62:5703–5710
  32. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res. 2002;8:1720–1730
  33. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669–1675
  34. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  35. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5:199–207
  36. Ratcliffe N, Wells W, Wheeler K, Memoli V. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol. 1997;10:1247–1252
  37. Corzo C, Tusquets I, Suarez M, Fabregat X, Salido M, Solé F, et al. Intratumoral heterogeneity of HER2/neu and topoisomerase IIa in breast cancer: a case with clonal monosomy 17. Cancer Genet Cytogenet. 2004;154:89–90
  38. Blend MJ, Stastny JJ, Swanson SM, Brechbiel MW. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm. 2003;18:355–363
  39. Hall EJ. Radiobiology for the radiologist. 5th ed.. Philadelphia: Lippincott Williams & Wilkins; 2000;
  40. Strickland DK, Vaidyanathan G, Zalutsky MR. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res. 1994;54:5414–5419
  41. Vaidyanathan G, Larsen RH, Zalutsky MR. 5-[211At]astato-2′-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 1996;56:1204–1209
  42. Carlin S, Akabani G, Zalutsky MR. In vitro cytotoxicity of [211At]-astatide and [131I]-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med. 2003;44:1827–1838
  43. Mothersill C, Seymour C. Radiation-induced bystander effects: past history and future directions. Radiat Res. 2001;155:759–767
  44. Goldberg Z, Lehnert BE. Radiation-induced effects in unirradiated cells: a review and implications in cancer. Int J Oncol. 2002;21:337–349
  45. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med. 2004;6:937–947
  46. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22:322–329

PII: S0969-8051(05)00301-X

doi: 10.1016/j.nucmedbio.2005.12.006

Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 333-347 , April 2006

Article Tools

* Image Usage & Resolution